VTGN vs WVE

VistaGen Therapeutics, Inc. vs Wave Life Sciences Ltd. — Valuation Comparison 2026

VTGN

Biotechnology
VistaGen Therapeutics, Inc.
Quality
6.0
out of 10
Value Trap
32
LOW
Price
$0.63
Last close
Models
9/13
Active
VS

WVE

Biotechnology
Wave Life Sciences Ltd.
Quality
6.7
out of 10
Value Trap
30
LOW
Price
$6.47
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType VTGN Fair ValueVTGN Upside WVE Fair ValueWVE Upside
Bayesian DCF Intrinsic $0.81 +27.9% $3.25 -49.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.62 +313.1% $3.72 -42.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VTGN vs WVE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VTGN vs WVE — Which Stock Is More Undervalued?

WVE scores higher with a 6.7/10 quality rating vs VTGN's 6.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VistaGen Therapeutics, Inc. (VTGN) and Wave Life Sciences Ltd. (WVE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VTGN currently trades at $0.63 with a QOC of 6.0/10, while WVE trades at $6.47 with a QOC of 6.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).